I-Sense
i-SENS is a South Korea-based, KOSDAQ-listed in vitro diagnostics company that develops, manufactures, and globally distributes blood glucose monitors (CareSens), continuous glucose monitors (CareSens Air), point-of-care analyzers (i-Smart, A1Care, ivisen), and veterinary diagnostics to patients, hospitals, and clinics across 110+ countries.
- Company typePublic
- Founded2000
- HeadquartersSeocho, South Korea
- Headcount501–1,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What I-Sense does
i-SENS, Inc. (KOSDAQ: 266470, formerly Precision Biosensor, Inc.) is a South Korea-headquartered, publicly traded in vitro diagnostics company founded in 2000 that develops, manufactures, and globally commercializes biosensor-based medical devices across four product pillars. Its flagship CareSens line of blood glucose monitoring systems (BGMS), including CareSens N, N Premier, N Voice, Dual, and Expert Plus variants using proprietary GDH-FAD enzyme chemistry, anchors the business with ISO 15197:2013-compliant accuracy and minimal sample volumes (0.5 µL). The second pillar is the CareSens Air continuous glucose monitoring system (CGM), Korea's first domestically developed CGM, which provides real-time glucose data and trend analysis via smartphone (with Galaxy Watch and Apple Watch support) and a dedicated standalone receiver; an upgraded version approved in Korea (March 2025) and CE-marked the same month eliminated fingerprick calibration and reduced warm-up from 2 hours to 30 minutes. The third pillar is point-of-care IVD systems—i-Smart blood gas and electrolyte analyzers, A1Care clinical chemistry, ivisen IA-1100 immunoassay, and Coag-Sense PT/INR—built around all-in-one cartridges integrating electrodes, reagents, and consumables for rapid testing in hospitals, clinics, and veterinary practices. The fourth is a connected software/data ecosystem (SmartLog, Sens365) enabling patient-provider data sharing and collaborative care.
The company operates a vertically integrated manufacturing footprint of over 2.1 billion annual blood glucose test strips capacity, anchored by Wonju and Songdo (Plant 1 and Plant 2, completed October 2023) in Korea, plus a China factory and Malaysian operations, supported by wholly-owned subsidiaries in the US (i-SENS USA, est. 2010; AgaMatrix, est. 2023; CoaguSense, est. 2016), Germany (i-SENS GmbH, est. 2016), China, India, Hong Kong, Chile, Mexico, and Peru. i-SENS generates revenue predominantly through hardware sales of meters, CGM sensors (KRW 6.7B in H1 2025, +88% YoY), and IVD cartridges on a per-unit pricing model, with subscription-adjacent software (SmartLog, Sens365) and a growing recurring consumables annuity from test strips and 14-day CGM sensors. Distribution combines direct sales to hospitals/clinics, regional subsidiary-led enterprise sales, and a global distributor network reaching 110+ countries, complemented by a transformational February 2026 partnership with LifeScan to commercialize i-SENS CGM technology under the OneTouch brand in Europe. FY2024 consolidated revenue reached $223.95M (up from $133.07M in 2018), with the company retaining undisputed leadership in Korea's BGMS market (31% share) while pivoting toward global CGM scale-up, which has driven significant near-term margin compression (operating profit fell from $21.08M in 2018 to $2.04M in 2024; consolidated net loss of $1.50M in 2024) as Songdo Plant 2 and CGM launch costs are absorbed.
I-Sense firmographics
Firmographics- Name
- I-Sense
- Legal name
- i-SENS, Inc.
- Website
- https://i-sens.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- i-SENS is a South Korea-based, KOSDAQ-listed in vitro diagnostics company that develops, manufactures, and globally distributes blood glucose monitors (CareSens), continuous glucose monitors (CareSens Air), point-of-care analyzers (i-Smart, A1Care, ivisen), and veterinary diagnostics to patients, hospitals, and clinics across 110+ countries.
- Ownership category
- akta.pro rank
I-Sense industry classification
Industry- Product category
- In Vitro Diagnostics / Diabetes Diagnostics Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
- akta.pro secondary industries
- Clinical Chemistry & Immunoassay Systems (HLAHAAAA), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
Keywords
Where I-Sense is headquartered
LocationHeadquarters
- HQ city
- Seocho
- HQ country
- South Korea
- HQ region
- Asia
Offices15 records
Markets served
I-Sense business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- Blood Glucose Monitoring Devices & Consumables: Sale of CareSens blood glucose monitors and proprietary test strips. The CareSens product line includes multiple models (CareSens N, N Premier, N Voice, Dual, PRO, Expert Plus) and associated strips. Annual production capacity exceeds 2.1 billion test strips.
- Continuous Glucose Monitoring System (CareSens Air): Sale of CareSens Air CGM sensors (14-day replacement cycle) and related receiver device. CGM sales reached KRW 6.7 billion in H1 2025 (88% YoY growth), already surpassing the total 2024 annual revenue of KRW 6.0 billion. The automated production line at Songdo Plant 2 supports 2 million units per year.
- IVD Analyzers & Cartridges: Sale of point-of-care diagnostic analyzers (i-Smart 30, i-Smart 300, i-SmartCare 10, A1Care, ivisen IA-1100, CareSign-V, VetMate) and their associated all-in-one cartridges. Targets hospitals, clinics, and veterinary practices.
- Software & Data Platforms: SmartLog diabetes management software for patients and healthcare providers (mobile and PC versions supporting multiple languages). Sens365 platform for CGM data interpretation and collaborative care. SmartLog is available on Android, iOS, Windows, and Mac.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | — | Pricing is distributor and market-dependent; no public list prices are available |
Go-to-market motion4 records
Distribution channels6 records
Marketing channels9 records
I-Sense product offering
Product offeringCore offering
i-SENS develops, manufactures, and commercializes biosensor-based in vitro diagnostic medical devices and consumables. Its portfolio covers self-monitoring blood glucose meters (CareSens BGMS), continuous glucose monitoring systems (CareSens Air), point-of-care IVD analyzers for hospitals/clinics (i-Smart, A1Care, ivisen IA-1100, Coag-Sense PT2), and companion-animal diagnostic systems (VetMate, i-Smart VET, CareSign-V), supported by SmartLog and Sens365 data platforms.
Product overview
i-SENS is a global in vitro diagnostics company that develops, produces, and commercializes biosensor-based medical devices. The product portfolio comprises four main categories: (1) Blood Glucose Monitoring Systems (BGMS) under the CareSens brand including CareSens N, CareSens N Premier, CareSens N Voice, CareSens Dual, and CareSens Expert Plus for self-monitoring of blood glucose; (2) Continuous Glucose Monitoring System (CGMS) featuring CareSens Air - Korea's first domestically developed CGM system - plus the Sens365 data platform and CareSens Air Receiver accessory; (3) IVD Systems for point-of-care testing including A1Care clinical chemistry analyzer, i-SmartCare 10 blood gas analyzer, i-Smart 30 PRO electrolyte analyzer, ivisen IA-1100 immunoassay analyzer, and Coag-Sense PT2 coagulation monitor; and (4) Veterinary Care Systems including VetMate blood glucose meter, i-Smart 300 VET and i-Smart 30 VET analyzers, and CareSign-V immunochemistry analyzer. The company leverages advanced biosensor and electrochemical technologies to deliver accurate, user-friendly diagnostic solutions across human and animal health markets.
Differentiator
Problem solved
Functional benefit
Brands
- CareSens: Self-monitoring blood glucose system brand meeting ISO 15197:2013 accuracy standards. Includes multiple product lines: CareSens N, CareSens N Voice, CareSens N Premier, CareSens Dual, CareSens PRO, CareSens Expert Plus, CareSens II Plus, and CareSens N Eco.
- CareSens Air
- VetMate
- i-Smart
- A1Care
- Coag-Sense
- CareSign-V
- ivisen IA-1100
- SmartLog
- Sens365
Products and services
- CareSens Blood Glucose Monitoring System (BGMS) Self-monitoring blood glucose system brand meeting ISO 15197:2013 accuracy standards; includes CareSens N, CareSens N Premier, CareSens N Voice, CareSens Dual, CareSens PRO, CareSens Expert Plus, CareSens II Plus, and CareSens N Eco models for home and professional BGM use.
- CareSens Air Continuous Glucose Monitoring System Korea's first domestically developed CGM with CE certification; provides real-time continuous glucose data, trend analysis, 14-day sensor wear, smartwatch compatibility (Galaxy Watch, Apple Watch), and a connected Sens365 data platform. The upgraded version (March 2025) eliminates finger-prick calibration and reduces warm-up time from 2 hours to 30 minutes.
- CareSens Air Receiver Dedicated standalone display device for the CareSens Air CGM sensor designed for elderly patients, children, and users without smartphone access; serves as a smartphone alternative for CGM data viewing and is required for insurance reimbursement in several European countries.
- SmartLog Diabetes Management Software
Quantifiable outcome
- CareSens won the Grand Prize at the First Brand Awards 2026 for the 15th consecutive year, with over 3.7 million consumers participating in the vote
- +5 more outcomes
Companies that use I-Sense
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
I-Sense technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability3 records
Feature7 records
I-Sense partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship and core.
- LifeScanflagshipLifeScan, a global leader in glucose monitoring with the OneTouch® brand (serving 20M+ people globally), partnered with i-SENS to launch a CGM system under the OneTouch® Vita brand. The partnership combines i-SENS's advanced CGM technology and manufacturing capacities with LifeScan's trusted brand and global distribution network. Products are expected to launch in Germany, Ireland, Portugal, and Belgium by early 2027, with expansion to additional markets planned. This partnership represents a transformational milestone for LifeScan's entry into the CGM market.
- AgaMatrix, Inc.corei-SENS acquired AgaMatrix, Inc. in 2023. AgaMatrix is a US-based company that had a longstanding supply agreement for BGMS test strips with i-SENS dating back to 2004. The acquisition strengthens i-SENS's presence and capabilities in the US diagnostics market.
- Korean Diabetes Association (KDA)corei-SENS hosted a Round Table Meeting (December 12, 2025) at its headquarters in collaboration with the Korean Diabetes Association, bringing together leading endocrinologists and diabetes experts to discuss evolving treatment paradigms and the clinical application of CGMS. Outcomes will be featured in the 2026 issue of Monthly Diabetes published by KDA.
- Korean Association of Diabetes Nurse Educators (KADNE)corei-SENS co-hosted the '2025 CareSens Air Symposium' (December 12-13, 2025) with KADNE, bringing together approximately 40 healthcare professionals and diabetes education nurses from major medical institutions across South Korea to exchange insights on clinical CGM utilization and future strategies.
- CoaguSense, Inc.corei-SENS acquired CoaguSense, Inc. in 2016. CoaguSense is a US-based company specializing in blood coagulation diagnostics. The acquisition enabled i-SENS to expand into the PT/INR blood coagulation monitoring market, resulting in the Coag-Sense PT2 product.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
I-Sense competitors and assessment
Company assessmentDirect peers
- Sinocare Inc. Sinocare is a leading Chinese BGMS manufacturer (Safe AQ/Smart series) with growing international distribution. As an Asia-headquartered BGMS peer, it is the most direct regional competitor to i-SENS CareSens across emerging markets.
- Ascensia Diabetes Care: Ascensia (Contour Next/PLUS series) is a dedicated BGMS competitor with a similar global distributor footprint and pharmacy channel positioning. It competes directly with i-SENS CareSens in the self-monitoring blood glucose category across emerging markets and Europe.
- Trividia Health: Trividia Health (TRUE METRIX, TRUEtrack) is a US-based BGMS manufacturer competing in pharmacy and retail channels. It is a direct product peer to i-SENS CareSens in the global BGMS category, particularly across value and consumer segments.
- Nova Biomedical: Nova Biomedical is a US-based manufacturer of blood glucose analyzers, hospital blood gas/electrolyte systems, and IVD point-of-care analyzers. Its StatStrip and Nova Max lines directly overlap with i-SENS's i-Smart, A1Care, and BGMS portfolios in hospital and POCT channels.
- Dexcom: Dexcom is the global leader in standalone continuous glucose monitoring (CGM) with G6/G7 sensors and a deeply entrenched US installed base. It is the primary direct competitor to i-SENS's CareSens Air CGM and the benchmark against which i-SENS's 10% global share target is measured.
- ACON Laboratories: ACON Laboratories manufactures ONETOUCH Ultra/Verio-equivalent BGMS strips and a broad IVD/rapid-test portfolio (Mission brand). It is a direct peer to i-SENS in BGMS, IVD reagents, and OEM strip supply, particularly through retail and emerging-market channels.
Broad incumbents
- Roche Diabetes Care: Roche's Accu-Chek brand is the legacy global leader in BGMS with deep hospital and consumer reach. As a broad diagnostics incumbent with adjacent IVD capabilities, it overlaps directly with i-SENS's BGMS, CGM, and POCT portfolios.
- Abbott Diabetes Care: Abbott's FreeStyle Libre franchise is the dominant global CGM platform, with Libre 2/3 sensors and broad international reimbursement. Abbott is also a broad diagnostics incumbent; it is the largest competitive threat i-SENS faces in CGM globally.
- LifeScan: LifeScan (OneTouch brand) is both i-SENS's CGM distribution partner (Feb 2026 OneTouch Vita launch in Europe) and a competing BGMS incumbent with global reach. The dual partner/competitor dynamic makes it a key comparable and counterparty in i-SENS's CGM economics.
Emerging players
- Ypsomed Holding AG: Ypsomed is a Swiss diabetes care company focused on insulin delivery (mylife YpsoPump) and connected diabetes management, with growing CGM-related partnerships. It is a comparable emerging diabetes-care player to i-SENS in Europe, though more delivery-oriented than BGMS/CGM.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
I-Sense social profiles
Digital presenceI-Sense compliance and trust
Trust signalCompliance5 records
I-Sense financial estimates
Financial estimateRevenue estimate
Valuation estimate
I-Sense leadership team
Management profileNumber of profiles
Profiles1 record
I-Sense subsidiaries and ownership
Company hierarchySubsidiaries12 records
I-Sense funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
I-Sense M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about I-Sense
What does I-Sense do?
i-SENS develops, manufactures, and commercializes biosensor-based in vitro diagnostic medical devices and consumables. Its portfolio covers self-monitoring blood glucose meters (CareSens BGMS), continuous glucose monitoring systems (CareSens Air), point-of-care IVD analyzers for hospitals/clinics (i-Smart, A1Care, ivisen IA-1100, Coag-Sense PT2), and companion-animal diagnostic systems (VetMate, i-Smart VET, CareSign-V), supported by SmartLog and Sens365 data platforms.
Is I-Sense a public or private company?
I-Sense is a public company. It is classified as public and is currently operating.
When was I-Sense founded?
I-Sense was founded in 2000. It employs 501 to 1,000 people.
Where is I-Sense based?
I-Sense is headquartered in Seocho, South Korea, in the Asia region.
How does I-Sense make money?
Four revenue lines are on record. Blood Glucose Monitoring Devices & Consumables are the primary driver. The others are continuous Glucose Monitoring System (CareSens Air), IVD Analyzers & Cartridges and software & Data Platforms.
Who are I-Sense's main competitors?
Direct peers on record are Sinocare Inc., Ascensia Diabetes Care, Trividia Health, Nova Biomedical, Dexcom and ACON Laboratories. Broad incumbents are Roche Diabetes Care, Abbott Diabetes Care and LifeScan. Ypsomed Holding AG is listed as an emerging player.
Does I-Sense have an API?
No public API is recorded for I-Sense.
What industry is I-Sense in?
I-Sense's product category is In Vitro Diagnostics / Diabetes Diagnostics Medical Devices. Its primary akta.pro industry code is HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers), with a secondary code of HLAHAAAA, Clinical Chemistry & Immunoassay Systems. Its NAICS code is 3391 and its SIC code is 3841.